However, pre-clinical studies with AML cell lines have shown that the action of the LSD1 inhibitors (developed to inhibit LSD1 demethylase activity) depends on inhibiting the interaction of LSD1 (in the CoREST complex) with the transcription factor GFI1B (or GF1) (see Figure 3). This evidence concerns the gene GFI1B and acute myeloid leukemia.